Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib vs Pertuzumab in Neoadjuvant Treatment of HER2+ Breast Cancer
NCT07797218Phase 3Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 3 trial of pyrotinib in breast cancer, sponsored by Shanghai Jiao Tong University School of Medicine. Started Jul 2026; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07797218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07797218.